Habits and timing

Caffeine, Hydration, And What They Actually Do To A Glucose Reading

Two ordinary morning habits, and two bodies of trial evidence that point in genuinely different directions. Caffeine, in a controlled human trial, made glucose tolerance measurably worse. Plain water, in a different controlled trial, made a fasting reading measurably better, in the specific group of people it was tested in. Both findings are small, both are real, and neither is the whole story on its own.

By GlucoPril Team · Last updated September 27, 2026 · 10 min read · Habits and timing

The caffeine trial: an actual morning-after test

A 2023 trial from the Norwegian School of Sport Sciences, published in Nutrients, ran a genuinely well-designed test of a question most people assume they already know the answer to. Eight healthy, physically active young men each came into the lab four separate mornings, after an overnight fast, in every combination of: caffeine or placebo, and exercise or no exercise the evening before. On each morning they took a standard oral glucose tolerance test — 75 g of glucose in solution, with blood drawn over the following hours.

Caffeine, dosed at 3 mg per kilogram of body weight (roughly the amount in two strong cups of coffee for an average adult), significantly increased the area under the glucose curve during the test — in plain terms, glucose stayed elevated for longer and went higher than it did without caffeine. This held true whether or not the person had done a substantial bout of cycling the evening before; the exercise session did not protect against or improve the caffeine effect, and did not significantly improve glucose tolerance on its own the next morning either.

Why caffeine does this, as best the data show

The same trial measured C-peptide, a marker of how much insulin the pancreas is actually releasing, and found no statistically significant difference with caffeine. That is a useful negative result: it suggests caffeine's effect on the glucose curve is not simply because the pancreas released less insulin. The trial also found diastolic blood pressure was slightly higher after caffeine. Together these point toward caffeine acting on insulin sensitivity at the tissue level — how well muscle and fat respond to the insulin that is released — rather than on the pancreas itself, which is consistent with the wider caffeine-and-glucose literature this trial cites as its starting premise, though this single trial does not resolve the mechanism on its own.

The paradox: habitual coffee drinkers have lower diabetes risk, long term

Here is the detail that makes the caffeine trial above genuinely interesting rather than simply a reason to quit coffee. A 2014 dose-response meta-analysis in Diabetes Care, pooling 28 prospective cohort studies with over 1.1 million participants and 45,335 incident cases of type 2 diabetes, found the opposite pattern for habitual, long-term coffee drinking: each additional cup a day was associated with a lower risk of developing type 2 diabetes, in a clear dose-response relationship — people drinking six cups a day had roughly a third lower relative risk than those drinking none. The genuinely striking part is that decaffeinated coffee showed almost the same protective association as caffeinated coffee (a relative risk of 0.94 per cup versus 0.91, a difference the authors found was not statistically significant).

Read next to the 2023 trial above, these two findings are not a contradiction so much as two different questions with two different answers. Acutely, on one morning, a caffeine dose measurably worsens how well the body handles a glucose load, in a mechanism that trial's own data suggest sits outside the pancreas. Chronically, over years, people who habitually drink coffee — caffeinated or not — tend to develop type 2 diabetes less often, which points toward some other compound in coffee, not caffeine itself, driving the long-term association. Both findings can be true at once, because they were never measuring the same thing.

The water trial: a hormone, not just a habit

Plain water intake has its own, separate trial literature, and it starts from a specific hormonal mechanism rather than a general folk claim that “staying hydrated helps blood sugar.” Low water intake raises a hormone called vasopressin, and copeptin, a stable marker that tracks vasopressin levels, has been linked in population studies to a higher risk of developing type 2 diabetes. A 2019 pilot trial from Lund University, published in the Journal of Clinical Endocrinology & Metabolism, tested whether deliberately adding water would lower copeptin, and, as a secondary outcome, whether fasting glucose moved with it.

Thirty-one adults with elevated copeptin added about 1.5 litres of water a day on top of their normal intake for six weeks. Their measured water intake rose from roughly 0.43 to 1.35 litres a day, urine osmolality fell sharply, and copeptin dropped from a median of 12.9 to 7.8 pmol/L. Fasting plasma glucose fell too, from a mean of 5.94 to 5.74 mmol/L (about 107 to 103 mg/dL) — a small change, but a statistically significant one, and the researchers found it was most pronounced in the participants who had started with the highest copeptin.

Who that water trial actually studied

The detail easiest to miss in a headline is who this trial actually enrolled: not a general population sample, but 31 adults specifically selected because a population survey had already flagged them with elevated copeptin and a current urine test confirmed they were concentrated (under-hydrated) at the time of enrolment. This was also explicitly labelled a pilot study by its own authors, with the stated purpose of testing whether the intervention was feasible and worth a larger trial, not a definitive answer for everyone. A person who already drinks plenty of water and has normal copeptin was not who this trial was about, and there is no published trial evidence here that adding more water on top of already-adequate intake produces the same drop.

Reading the two findings side by side

Neither trial is large. Both used a real physiological measurement rather than a self-reported outcome, which is worth more than the small sample size might suggest at first glance.

A specific, practical wrinkle: the morning of a lab test

One place the 2023 caffeine trial's finding has an immediate, practical edge is the morning of an actual fasting glucose or oral glucose tolerance test at a clinic. The trial's own protocol is close to that exact scenario: an overnight fast, caffeine (or not) roughly 30 minutes before, then a standard 75 g glucose tolerance test. Many people have their usual coffee on the way to or in the waiting room before this kind of test without a second thought, and this trial's result — a significantly larger area-under-the-curve for glucose with caffeine on board — is a direct reason a clinic might ask a patient to skip coffee before the test, not because caffeine is harmful, but because it can shift the very number the test is trying to measure cleanly. That is a different, narrower point than the one about habitual, long-term coffee drinking above, and the two should not be confused with each other.

What this means for an actual morning

Two specific, narrow, trial-backed points, not a general theory of blood sugar. A dose of caffeine roughly equivalent to a strong coffee measurably worsened how well a group of healthy young men handled a glucose load the next morning, regardless of whether they had exercised the evening before — worth knowing before a fasting glucose test taken with the usual cup of coffee beforehand. Separately, in people who are measurably under-hydrated, closing that gap with plain water measurably lowered fasting glucose over six weeks in one pilot trial. Neither finding says anything about this bottle's own seven extracts, and neither is a substitute for reading what those extracts' own trials found.

References